The scientific discipline studying the molecular mechanisms, pathways, and mediators involved in inflammatory resolution, with particular focus on specialized pro-resolving mediators (SPMs) and their biosynthetic pathways. Resolvomics investigates how acute inflammation actively transitions to resolution through lipid mediator class switching, cellular reprogramming, and energy-dependent clearance processes. This field reveals that chronic disease represents not excessive inflammation, but failed resolution.
Think of inflammation like a construction site after demolition. The old building (damaged tissue) has been torn down by the wrecking crew (neutrophils, pro-inflammatory prostaglandins). But resolution isn't just "stopping" demolition—it's an entirely different crew arriving with blueprints and tools. Resolvomics studies this second crew: the cleanup team that removes debris (efferocytosis), the inspectors who signal "all clear" (SPMs binding to resolution receptors), and the renovation workers who rebuild (M2 macrophages). The foreman switches the work order from demolition to construction—that's lipid mediator class switching. If the demolition crew never leaves and the construction crew never arrives, you get a permanent disaster zone (chronic inflammation). Measuring SPM levels is like checking if the construction permits were issued—without them, healing can't proceed no matter how many anti-inflammatory drugs (demolition stop orders) you issue.
Resolvomics centers on the active biochemical transition from pro-inflammatory to pro-resolving lipid mediators:
Phase 1: Inflammatory Initiation
Phase 2: Lipid Mediator Class Switching
- COX-2 undergoes S-nitrosylation (via Nitric Oxide) → loses PGE2 synthesis capacity, gains 15R-HETE production
- Acetylation of COX-2 by aspirin → produces aspirin-triggered lipoxins and resolvins
- 15-LOX and 12-LOX become dominant enzymes
- Substrate switch: Omega-3 fatty acids (EPA, DHA) become primary substrates instead of arachidonic acid
Phase 3: SPM Biosynthesis
From EPA:
From DHA:
From arachidonic acid (late phase):
Phase 4: Resolution Effector Functions
SPM receptor signaling triggers:
graph TD
A[SPMs bind resolution receptors] --> B[ERV1/ChemR23]
A --> C[DRV1/GPR32]
A --> D[ALX-FPR2]
B --> E["↓ Neutrophil infiltration"]
B --> F["↑ Macrophage phagocytosis"]
C --> G["↓ PMN transmigration"]
C --> H["↑ Efferocytosis"]
C --> I["↓ NF-κB activation"]
D --> J[Stop neutrophil recruitment]
D --> K[Stimulate non-phlogistic monocyte recruitment]
E --> L[Resolution Phase]
F --> L
G --> L
H --> L
I --> L
J --> L
K --> L
L --> M["M1→M2 macrophage polarization"]
M --> N[Apoptotic neutrophil clearance]
N --> O[Tissue repair initiated]
Cellular Resolution Mechanisms:
- M1-M2-macrophage-polarization: M1 (pro-inflammatory) → M2 (pro-resolving) phenotype shift
- M2 macrophages upregulate scavenger receptors, TGF-beta, IL-10
- Efferocytosis: apoptotic neutrophil clearance without secondary necrosis (prevents autoantigen exposure)
- Neutrophil apoptosis signaled by RvD1, RvE1 (via caspase-3 activation, ↓Bcl-2)
- Lymphatic drainage of cellular debris and fluid (resolution of edema)
Energy Requirements:
- Resolution is ATP-dependent (phagocytosis, lipid biosynthesis, active transport)
- Requires mitochondrial function for SPM synthesis (15-LOX, 12-LOX are energy-consuming)
- Immunometabolism shift: from glycolytic (M1) to oxidative phosphorylation (M2)
SPM Metabolic Inactivation:
- SPMs are rapidly metabolized (half-life: minutes to hours)
- Dehydrogenases convert bioactive SPMs to inactive derivatives
- Allows temporal control of resolution
Resolvomics fundamentally reframes chronic disease from "too much inflammation" to "too little resolution"—a paradigm shift with profound clinical implications:
Chronic Disease as Resolution Failure:
Resolution as Selfish System Dysregulation:
Diagnostic Applications:
- SPM profiling via lipidomics becoming clinical biomarker
- Resolution indices: RvE1/LTB4 ratio, MaR1 levels, efferocytosis markers (Annexin A1)
- Low SPM levels predict poor surgical outcomes, delayed wound healing, chronic pain development
- Omega-3 index <4% correlates with low SPM synthesis capacity
Therapeutic Insights from Resolvomics:
Why NSAIDs and ice may impair healing:
- NSAIDs block COX-2 entirely → prevent both PGE2 (needed early) and 15R-HETE (needed for lipoxin synthesis)
- Studies show NSAIDs delay fracture healing, tendon repair, muscle regeneration
- Ice/cryotherapy suppresses local metabolism → reduces enzymatic SPM synthesis
- Resolution Pharmacology: shift from anti-inflammatory to pro-resolving strategies
Omega-3 as Resolution Substrate:
- Omega-3 fatty acids deficiency = substrate starvation for SPM synthesis
- Clinical threshold: EPA+DHA >2g/day for measurable SPM production
- Omega-3 index >8% optimal for resolution capacity
- Marine sources preferred (pre-formed EPA/DHA vs. inefficient ALA conversion)
Movement as Pro-Resolution Therapy:
- Pain-free movement from day 1 post-injury promotes SPM synthesis
- Mechanical loading → myokine release → SPM upregulation
- Immobilization or excessive rest → resolution failure
Intervention Hierarchy (Resolution-Based):
- Substrate provision: Omega-3 (2-4g EPA+DHA daily), vitamin D (cofactor for 15-LOX)
- Avoid resolution inhibitors: minimize NSAIDs, avoid ice beyond acute phase (<24h), address chronic stress
- Promote resolution mediators: specialized pro-resolving mediator supplementation (experimental), aspirin low-dose (aspirin-triggered SPMs)
- Support efferocytosis: ensure adequate sleep (↑ glucocorticoid receptor sensitivity for M2 polarization), manage blood glucose (hyperglycemia impairs phagocytosis)
- Address failed resolution systemically: gut barrier restoration (stops LPS re-triggering), HPA-axis rehabilitation, circadian rhythm optimization
Metamodel Connections:
- Metamodel 5 (Systems Biology): resolution as emergent property of immune-metabolic-neuro crosstalk
- Mismatch paradigm: evolutionary novelty of high omega-6:omega-3 ratios (ancestral ~1:1, modern ~20:1) impairs SPM synthesis
- Intermittent Living: ancient humans experienced intermittent inflammation (injury, infection) with full resolution between events; modern chronic low-grade inflammation = continuous demolition without construction
- SPM families include E-series and D-series resolvins, protectins, maresins, lipoxins, and cysteinyl-SPMs
- Lipid mediator class switching occurs via COX-2 post-translational modification: S-nitrosylation and acetylation redirect enzymatic activity from PGE2 to 15R-HETE production
- Resolution is an active, energy-requiring process—not passive inflammation decay—requiring ATP, enzymatic cascades, and cellular reprogramming
- Efferocytosis capacity: each M2 macrophage clears 3-5 apoptotic neutrophils without triggering secondary inflammation
- SPM synthesis requires omega-3 index >8% (red blood cell membrane EPA+DHA); deficiency (<4%) impairs resolution by 60-80%
- NSAIDs block COX-2 indiscriminately → prevent lipoxin synthesis → delay healing by 30-50% in fracture/tendon studies
- Aspirin uniquely acetylates COX-2 → produces aspirin-triggered resolvins (AT-RvD1) with 10-100x greater potency than native SPMs
- Resolution phase peaks 12-48 hours post-injury if substrate and enzymes present; failed resolution → chronic inflammation by 72-96 hours
- Clinical SPM levels: RvD1 >100 pg/mL, MaR1 >50 pg/mL correlate with successful resolution; <50% of these values predict chronicity
- M1-M2-macrophage-polarization regulated by SPMs: RvD1 shifts M1→M2 via ↓NF-kB, ↑SOCS3, altered immunometabolism (glycolysis → oxidative phosphorylation)
- specialized pro-resolving mediators — the molecular mediators studied in resolvomics, including all SPM families
- resolvins — major D-series and E-series SPM families synthesized from DHA and EPA via 15-LOX pathway
- protectins — neuroprotective SPMs (NPD1/PD1) derived from DHA, particularly relevant in CNS inflammation resolution
- maresins — macrophage-derived SPMs (MaR1, MaR2) that promote M2 polarization and efferocytosis
- lipoxins — first-discovered SPMs from arachidonic acid, produced via transcellular biosynthesis between neutrophils and platelets
- cysteinyl-SPMs — SPM-amino acid conjugates (RvD5n-3 DPA) with enhanced stability and receptor affinity
- lipid mediator class switching — the central mechanistic process defining transition from inflammatory to resolving phase, studied extensively in resolvomics
- M1-M2-macrophage-polarization — cellular resolution mechanism where M1 (pro-inflammatory) macrophages reprogram to M2 (pro-resolving) phenotype in response to SPMs
- Efferocytosis — clearance of apoptotic neutrophils by M2 macrophages without secondary inflammation, essential resolution endpoint
- ERV1-ChemR23-receptor — G-protein coupled receptor for E-series resolvins (RvE1), signals to stop neutrophil infiltration
- ALX-FPR2-receptor — promiscuous resolution receptor binding lipoxins, RvD1, and annexin A1, critical for efferocytosis initiation
- DRV1-GPR32-receptor — D-resolvin receptor (GPR32) mediating anti-inflammatory and pro-resolving signals of RvD1-RvD5
- Omega-3 fatty acids — essential substrates for SPM biosynthesis; EPA and DHA deficiency = resolution substrate starvation
- NSAIDs — non-selective COX inhibitors that block both inflammatory PGE2 and pro-resolving lipoxin synthesis, impairing healing
- chronic inflammation — understood through resolvomics as failed resolution rather than excessive initiation
- wound healing — resolution-dependent process requiring SPM-mediated neutrophil apoptosis, efferocytosis, and M2 macrophage activation
- Resolution Pharmacology — emerging therapeutic field applying resolvomics insights: SPM agonists, resolution receptor activation
- immunometabolism — metabolic reprogramming from glycolysis (M1) to oxidative phosphorylation (M2) during resolution, studied in resolvomics
- COX-2 — dual-function enzyme central to resolvomics: generates PGE2 early, then 15R-HETE for lipoxin synthesis after post-translational modification
- 15-LOX — key resolution enzyme converting DHA to 17-HDHA (resolvin precursor) and EPA to 18-HEPE
- acute inflammation — the physiological inflammatory response that, when properly resolved via SPM pathways, prevents chronic disease
- inflammatory resolution — the active biological process studied by resolvomics, distinct from inflammation cessation
- aspirin — unique NSAID that acetylates COX-2 to produce aspirin-triggered resolvins with enhanced potency
- neutrophil — first-responder immune cell whose apoptosis and clearance is essential resolution checkpoint, regulated by SPMs
- macrophage — central resolution effector cell undergoing M1→M2 phenotype switch in response to SPM receptor signaling
- leukotrienes — pro-inflammatory lipid mediators (LTB4) that must be suppressed during lipid mediator class switching
- prostaglandins — early inflammatory mediators (PGE2) whose synthesis pathway is redirected during resolution phase
- inflammation — acute inflammatory response is prerequisite for resolution; resolvomics studies how inflammation transitions to repair